Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City, 51642-51643 [2017-24201]

Download as PDF 51642 Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–442 and 731– TA–1095–1096 (Second Review)] Lined Paper School Supplies From China and India; Amended Schedule for Expedited Reviews United States International Trade Commission. ACTION: Notice. AGENCY: DATES: October 27, 2017. FOR FURTHER INFORMATION CONTACT: Calvin Chang (202–205–3062), Office of Investigations, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436. Hearingimpaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202– 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https:// www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. SUPPLEMENTARY INFORMATION: On October 6, 2017, the Commission established a schedule for conducting expedited reviews on lined paper school supplies from China and India. On October 26, 2017, the schedule was published in the Federal Register (82 FR 49659). This notice corrects several dates in the previously-published schedule. In particular, the staff report containing information concerning the subject matter of the review will be placed in the nonpublic record on January 3, 2018 and made available to persons on the Administrative Protective Order service list for this review. Comments pursuant to section 207.62(d) of the Commission’s rules are due on or before January 9, 2018. The Commission has determined that these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B). For further information concerning these investigations see the Commission’s notice cited above. Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules. By order of the Commission. Issued: November 1, 2017. Lisa R. Barton, Secretary to the Commission. [FR Doc. 2017–24174 Filed 11–6–17; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with on or before January 8, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. Comments and requests for hearings on applications to import raw material are not appropriate. 72 FR 3417 (January 25, 2007). SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on June 12, 2017, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: DATES: ethrower on DSK3G9T082PROD with NOTICES Controlled substance Drug code Gamma Hydroxybutyric Acid ........................................................................................................................................... Amphetamine ................................................................................................................................................................... Lisdexamfetamine ............................................................................................................................................................ Methylphenidate .............................................................................................................................................................. 4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... Phenylacetone ................................................................................................................................................................. Cocaine ............................................................................................................................................................................ Codeine ........................................................................................................................................................................... Oxycodone ....................................................................................................................................................................... Hydromorphone ............................................................................................................................................................... Hydrocodone ................................................................................................................................................................... Morphine .......................................................................................................................................................................... Oripavine ......................................................................................................................................................................... Thebaine .......................................................................................................................................................................... Opium extracts ................................................................................................................................................................ Opium fluid extract .......................................................................................................................................................... Opium tincture ................................................................................................................................................................. Opium, powdered ............................................................................................................................................................ Oxymorphone .................................................................................................................................................................. Noroxymorphone ............................................................................................................................................................. Fentanyl ........................................................................................................................................................................... VerDate Sep<11>2014 17:29 Nov 06, 2017 Jkt 244001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1 2010 1100 1205 1724 8333 8501 9041 9050 9143 9150 9193 9300 9330 9333 9610 9620 9630 9639 9652 9668 9801 Schedule I II II II II II II II II II II II II II II II II II II II II Federal Register / Vol. 82, No. 214 / Tuesday, November 7, 2017 / Notices The company plans to manufacture the listed controlled substances in bulk for sale to its customers, for dosage form development, for clinical trials, and for use in stability qualification studies. Dated: October 30, 2017. Demetra Ashley, Acting Assistant Administrator. [FR Doc. 2017–24201 Filed 11–6–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB Number 1110–0060] Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection—CJIS Name Check Form (1–791) Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice. ACTION: 60-Day notice. AGENCY: The Department of Justice (DOJ), Federal Bureau of Investigation (FBI), Criminal Justice Information Services (CJIS) Division, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. DATES: Comments are encouraged and will be accepted for 60 days until January 8, 2018. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Gerry Lynn Brovey, Supervisory Information Liaison Specialist, FBI, CJIS, Resources Management Section, Administrative Unit, Module C–2, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306 (facsimile: 304–625– 5093) or email glbrovey@ic.fbi.gov. Written comments and/or suggestions can also be sent to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted via email to OIRA_ submission@omb.eop.gov. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning ethrower on DSK3G9T082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:29 Nov 06, 2017 Jkt 244001 the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information collection: (1) Type of Information Collection: Revision of a currently approved collection in use without an OMB control number. (2) The Title of the Form/Collection: CJIS Name Check Request. (3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: 1–791. (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Agencies authorized to submit applicant fingerprints into the Next Generation Identification (NGI) system for noncriminal justice purposes such as employment, benefits, and licensing. This form is completed to obtain a name check for an applicant when the fingerprints have been rejected twice for quality to ensure eligible individuals are not denied employment, benefits, or licensing. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: It is estimated that 77,816 respondents will complete each form within approximately 5 minutes. (6) An estimate of the total public burden (in hours) associated with the collection: There are an estimated 6,485 total annual burden hours associated with this collection. If additional information is required contact: Melody Braswell, Department Clearance Officer, United States PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 51643 Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., 3E.405A, Washington, DC 20530. Dated: November 2, 2017. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2017–24208 Filed 11–6–17; 8:45 am] BILLING CODE 4410–02–P DEPARTMENT OF JUSTICE Notice of Lodging of Proposed Consent Decree Under the Clean Air Act On October 31, 2017, the Department of Justice lodged a proposed consent decree with the United States District Court for the Southern District of Texas in the lawsuit entitled United States and the Louisiana Department of Environmental Quality v. Exxon Mobil Corp. and ExxonMobil Oil Corp., Civil Action No. 4:17-cv-03302. The United States and Louisiana Department of Environmental Quality filed this lawsuit under the Clean Air Act and Louisiana Environmental Quality Act. The complaint seeks injunctive relief and civil penalties based on violations of the Clean Air Act’s New Source Review requirements, New Source Performance Standards, National Emissions Standards for Hazardous Air Pollutants, ‘‘Title V’’ program requirements and operating permits, and related Texas and Louisiana state implementation plan requirements. The alleged violations involve flares used at petrochemical manufacturing plants owned and operated by the defendants, Exxon Mobil Corp. and ExxonMobil Oil Corp., in Baytown and Beaumont, Texas, and Baton Rouge, Louisiana. The consent decree requires the defendants to perform injunctive relief, pay a $2,500,000 civil penalty, perform a Supplemental Environmental Project in Baytown, Texas, and two Beneficial Environmental Projects in Louisiana. The publication of this notice opens a period for public comment on the proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States and the Louisiana Department of Environmental Quality v. Exxon Mobil Corp. and ExxonMobil Oil Corp., D.J. Ref. No. 90–5–2–1–10128. All comments must be submitted no later than thirty (30) days after the publication date of this notice. E:\FR\FM\07NON1.SGM 07NON1

Agencies

[Federal Register Volume 82, Number 214 (Tuesday, November 7, 2017)]
[Notices]
[Pages 51642-51643]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24201]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Cambrex 
Charles City

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with on or before 
January 8, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. Comments and 
requests for hearings on applications to import raw material are not 
appropriate. 72 FR 3417 (January 25, 2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on June 
12, 2017, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 
50616 applied to be registered as a bulk manufacturer of the following 
basic classes of controlled substances:

 
------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid..........            2010  I
Amphetamine........................            1100  II
Lisdexamfetamine...................            1205  II
Methylphenidate....................            1724  II
4-Anilino-N-phenethyl-4-piperidine             8333  II
 (ANPP).
Phenylacetone......................            8501  II
Cocaine............................            9041  II
Codeine............................            9050  II
Oxycodone..........................            9143  II
Hydromorphone......................            9150  II
Hydrocodone........................            9193  II
Morphine...........................            9300  II
Oripavine..........................            9330  II
Thebaine...........................            9333  II
Opium extracts.....................            9610  II
Opium fluid extract................            9620  II
Opium tincture.....................            9630  II
Opium, powdered....................            9639  II
Oxymorphone........................            9652  II
Noroxymorphone.....................            9668  II
Fentanyl...........................            9801  II
------------------------------------------------------------------------


[[Page 51643]]

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers, for dosage form development, for 
clinical trials, and for use in stability qualification studies.

    Dated: October 30, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-24201 Filed 11-6-17; 8:45 am]
BILLING CODE 4410-09-P